Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

denovoMATRIX releases isoMATRIX: Cell and Gene Therapy’s first high-yield MSC isolation technology

December 15, 2021 By Cade Hildreth, Founder & President Leave a Comment

DRESDEN, Germany, December 15, 2021 / BioInformant / — denovoMATRIX GmbH, an innovator in cell and gene therapy (CGT) manufacturing, announced the launch of a new technology for bringing down costs and increasing access to high-quality mesenchymal stromal cells (MSCs) for stem cell-based therapies. The technology termed isoMATRIX, is designed to isolate MSCs in xeno-/serum-free conditions with high efficiency and stemness enabling rapid cell expansion for radically reduced cost of goods (COGs) for cell therapy manufacturers.

[Read more…]

Therapeutic Solutions Utilizes MSC Exosomes to Suppress Inflammatory Pathologies

October 18, 2021 By Cade Hildreth, Founder & President Leave a Comment

Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production
Patent Filed on Potential Solution to Cause of Major Inflammatory Pathologies

ELK CITY, Idaho, Oct. 4, 2021 — Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced laboratory data demonstrating that exosomes produced by JadiCells™, the Company’s Phase III cell therapy candidate for COVID-19 and other lung pathology, as well as mesenchymal stem cells proprietary to the Company, can suppress the production of neutrophil extracellular traps. [Read more…]

Meet the New York Scientist Using Stem Cells as a Treatment For MS

September 6, 2021 By Cade Hildreth, Founder & President 9 Comments

Treatment for multiple sclerosis (MS) is an evolving area and one in which new therapeutic approaches are rapidly advancing. Led by Dr. Saud Sadiq, the Tisch MS Research Center of New York is pursuing a Phase II clinical trial exploring the use of stem cell technology for the treatment for MS. The announcement followed positive results from an FDA-approved Phase I stem cell trial for MS. [Read more…]

RoosterBio Releases RoosterGEM™, Cell and Gene Therapy’s First Complete Transduction Medium

May 21, 2021 By Cade Hildreth, Founder & President Leave a Comment

RoosterGEM™, a complete genetic engineering medium, empowers product developers to realize up to four-fold increased transduction efficiency in primary cells, and achieve a greater than 50% reduction in overall gene transfer cost.

Frederick, MD, May 20, 2021 – RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems for cell and gene therapy product developers, today announced the launch of its product RoosterGEM™, a stand-alone, complete gene transfer medium that is optimized to remove key challenges in primary cell genetic modification. [Read more…]

Landmark MSC Trial for Parkinson’s Disease Authorized by U.S. FDA

April 30, 2021 By Cade Hildreth, Founder & President Leave a Comment

April 28, 2021, SUGAR LAND, Texas — Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson’s Disease.

The trial is the first globally to administer pure adipose-derived mesenchymal stem cells to Parkinson’s patients in such high quantities over repeat treatments. Twenty-four patients will be randomized to receive six intravenous infusions of 200 million stem cells each. [Read more…]

Mesenchymal Stem Cells (MSCs)

Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production

Patent Filed on Potential Solution to Cause of Major Inflammatory Pathologies

RoosterGEM™, a complete genetic engineering medium, empowers product developers to realize up to four-fold increased transduction efficiency in primary cells, and achieve a greater than 50% reduction in overall gene transfer cost.